Target Name: LMNTD2-AS1
NCBI ID: G692247
Review Report on LMNTD2-AS1 Target / Biomarker Content of Review Report on LMNTD2-AS1 Target / Biomarker
LMNTD2-AS1
Other Name(s): LMNTD2 antisense RNA 1, transcript variant 1 | LMNTD2-AS1 variant 2 | LMNTD2 antisense RNA 1 | LMNTD2 antisense RNA 1, transcript variant 2 | LMNTD2-AS1 variant 1

LMNTD2-AS1: A Potential Drug Target and Biomarker

Introduction

L-myelin basic neuron degeneration (L-myelin basic neuron degeneration, LSNP) is an inherited neurodegenerative disease that mainly manifests as motor neuron disease and often leads to death. The mechanism by which LSNP occurs is not fully understood, but is known to be closely related to neuronal membrane potential (NMEA). Many studies have suggested that LSNP may be a neurodegenerative disease primarily characterized by neuronal death and neuronal loss.

In recent years, researchers have discovered that LMNTD2 is a new gene that plays an important role in LSNP. LMNTD2 is an RNA molecule that functions to encode a protein that resists neuronal loss. LMNTD2 RNA molecules can be expressed to treat LSNP.

LMNTD2-AS1: a molecule to watch

LMNTD2-AS1 is a transcript variant of LMNTD2, which functions to protect neurons by encoding proteins that resist neuronal loss. The function of LMNTD2-AS1 has been confirmed, and it can significantly extend the survival time of neurons in LSNP animal models.

LMNTD2-AS1 functions by encoding a protein called NLRP1. NLRP1 is an important protein that plays an important role in neuronal death and neuronal loss. By encoding NLRP1, LMNTD2-AS1 can inhibit the self-destructive death of neurons, thereby prolonging the survival time of neurons.

LMNTD2-AS1 expression is also subject to some regulation. Studies have shown that the expression of LMNTD2-AS1 is affected by

Protein Name: LMNTD2 Antisense RNA 1

The "LMNTD2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMNTD2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMO1 | LMO2 | LMO3 | LMO4 | LMO7 | LMO7-AS1 | LMO7DN | LMOD1 | LMOD2 | LMOD3 | LMTK2 | LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249